|  |  |  |  |
| --- | --- | --- | --- |
| **Hypertension:** | | | |
| Group: | Baseline | +1-year | +2-year |
| Active | 8 / 230 | 19 / 212 | 15 / 202 |
| Control | 12 / 161 | 9 / 133 | 10 / 122 |
| Intervention | 13 / 183 | 16 / 167 | 17 / 145 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Dyslipidemia:** | | | |
| Group: | Baseline | +1-year | +2-year |
| Active | 22 / 230 | 28 / 212 | 26 / 202 |
| Control | 14 / 161 | 16 / 133 | 14 / 122 |
| Intervention | 14 / 183 | 15 / 167 | 20 / 145 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Diabetes:** | | | |
| Group: | Baseline | +1-year | +2-year |
| Active | 3 /230 | 4 / 212 | 2 / 202 |
| Control | 1 / 161 | 2 / 133 | 1 / 122 |
| Intervention | 1 / 183 | 2 / 167 | 0 / 145 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Hypertension:** | | | |
| Group: | Baseline | +1-year | +2-year |
| Active | 8 / 194 | 18 / 194 | 15 / 194 |
| Control | 8 / 117 | 8 / 117 | 8 / 117 |
| Intervention | 11 / 142 | 14 / 142 | 16 / 142 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Dyslipidemia:** | | | |
| Group: | Baseline | +1-year | +2-year |
| Active | 21 / 194 | 27 / 194 | 26 / 194 |
| Control | 13 / 117 | 16 / 117 | 14 / 117 |
| Intervention | 9 / 142 | 11 / 142 | 20 / 142 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Diabetes:** | | | |
| Group: | Baseline | +1-year | +2-year |
| Active | 3 / 194 | 4 / 194 | 2 / 194 |
| Control | 1 / 117 | 1 / 117 | 1 / 117 |
| Intervention | 0 / 142 | 2 / 142 | 0 / 142 |